NfL makes regulatory debut as neurodegenerative disease biomarker

被引:22
|
作者
Mullard, Asher
机构
关键词
D O I
10.1038/d41573-023-00083-z
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The FDA approved tofersen for amyotrophic lateral sclerosis based on the drug’s ability to lower blood levels of neurofilament light (NfL) — establishing a proof of potential for this neuroscience biomarker that could have implications for other diseases of the brain.
引用
收藏
页码:431 / 434
页数:4
相关论文
共 50 条